MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-17-2025
Zynex Operating Income 2011-2026 | ZYXI
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Zynex
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.99 M | 10.8 M | 22.9 M | 22.4 M | 10.2 M | 11.1 M | 10.4 M | 8.94 M | 640 K | -2.48 M | -5.7 M | -7.6 M | 2.74 M | 3.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 22.9 M | -7.6 M | 6.67 M |
Quarterly Operating Income Zynex
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -44 M | -10.3 M | -13.1 M | - | 3.8 M | 2.23 M | 525 K | - | 5.48 M | 2.71 M | 284 K | - | 6.56 M | 4.36 M | 1.91 M | 11.6 M | 8.05 M | 3.81 M | -1.08 M | 2.3 M | 1.41 M | 4.08 M | 2.46 M | 3.73 M | 2.5 M | 2.58 M | 2.26 M | 2.88 M | 2.82 M | 2.72 M | 1.96 M | 3.59 M | 2.94 M | 1.93 M | 483 K | 518 K | 622 K | -150 K | -350 K | - | -226 K | -363 K | -772 K | - | 412 K | -5.42 M | -1.29 M | - | -1.07 M | -2.56 M | -362 K | - | 712 K | 932 K | 486 K | - | 1.1 M | 899 K | -139 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.6 M | -44 M | 323 K |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Align Technology
ALGN
|
608 M | $ 176.83 | 5.97 % | $ 13.2 B |  USA |
 |
Alphatec Holdings
ATEC
|
-82.1 M | $ 11.66 | 5.71 % | $ 1.75 B | USA |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
AxoGen
AXGN
|
-7.85 M | $ 34.0 | 9.71 % | $ 1.57 B | USA |
 |
AdaptHealth Corp.
AHCO
|
90.9 M | $ 12.18 | 2.01 % | $ 1.65 B | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Bio-Rad Laboratories
BIO
|
269 M | $ 281.15 | 1.13 % | $ 7.93 B | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-14.7 M | $ 0.62 | 1.67 % | $ 38.6 M | USA |
 |
Bruker Corporation
BRKR
|
253 M | $ 38.25 | 4.31 % | $ 5.7 K | USA |
 |
Boston Scientific Corporation
BSX
|
3.61 B | $ 62.56 | 1.15 % | $ 92.6 B | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 24.4 | 2.61 % | $ 206 M | USA |
 |
Second Sight Medical Products
EYES
|
-27.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
ClearPoint Neuro
CLPT
|
-24.2 M | $ 9.17 | 1.1 % | $ 260 M | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
480 M | $ 91.96 | 2.13 % | $ 12.4 B | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
Inogen
INGN
|
-30.2 M | $ 6.67 | -1.91 % | $ 177 M | USA |
 |
Inspire Medical Systems
INSP
|
51 M | $ 53.38 | -1.89 % | $ 1.57 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
IRIDEX Corporation
IRIX
|
-2.57 M | $ 1.03 | - | $ 17.4 M | USA |
 |
Integer Holdings Corporation
ITGR
|
221 M | $ 87.48 | 2.78 % | $ 3.04 B | USA |
 |
Invacare Corporation
IVC
|
-80.5 M | - | - | $ 24.7 M | USA |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 16.01 | 1.59 % | $ 376 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
LivaNova PLC
LIVN
|
199 M | $ 64.66 | 1.76 % | $ 3.53 B |  Britain |
 |
LENSAR
LNSR
|
-24.6 M | $ 5.53 | -1.78 % | $ 66.1 M | USA |
 |
Butterfly Network
BFLY
|
-74.4 M | $ 4.14 | 2.22 % | $ 876 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-19.8 M | $ 3.37 | -0.88 % | $ 126 M |  France |
 |
Myomo
MYO
|
-14.4 M | $ 0.68 | 0.44 % | $ 28.5 M | USA |
 |
NanoVibronix
NAOV
|
-3.58 M | - | - | $ 1.08 M | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Delcath Systems
DCTH
|
660 K | $ 9.85 | 1.86 % | $ 353 M | USA |
 |
BioSig Technologies
BSGM
|
-71.1 M | - | 37.08 % | $ 85.7 M | USA |
 |
Natus Medical Incorporated
NTUS
|
23.8 M | - | 1.94 % | $ 1.05 B | USA |
 |
Nevro Corp.
NVRO
|
-126 M | - | - | $ 217 M | USA |